2-Ethynyl-5-methylpyrimidine | 1196146-85-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-Ethynyl-5-methylpyrimidine
• 英文别名: 2-ethynyl-5-methylpyrimidine
• CAS: 1196146-85-6
• 化学式: C₇H₆N₂
• 分子量: 118.14
• InChiKey: ZDVLJTIAKJAHJF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] AMINO-PYRIMIDONYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] DÉRIVÉS D'AMINO-PYRIMIDONYLE, PROCÉDÉ DE PRÉPARATION DE CEUX-CI ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：SERVIER LAB

  公开号：WO2020008013A1

  公开（公告）日：2020-01-09

  Compounds of formula (I), wherein R1, R2, R3, R4, R5, R6, J and n are as defined in the description. Medicaments.

  式(I)的化合物，其中R1、R2、R3、R4、R5、R6、J和n的定义如描述所示。药物。
• AMINO-PYRIMIDONYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：Les Laboratoires Servier

  公开号：EP3818054A1

  公开（公告）日：2021-05-12
• NON-SELECTIVE KINASE INHIBITORS
  申请人：ZIAMAN Lawrence

  公开号：US20150353527A1

  公开（公告）日：2015-12-10

  Disclosed herein are compounds, compositions, and methods for preventing and treating proliferative diseases associated with aberrant receptor tyrosine kinase (RTK) activity. The therapeutic indications described herein more specifically relate to the non-selective inhibition of RTKs associated with vascular and pulmonary disorders.
• Malononitrile Compounds for Controlling Animal Pests
  申请人：BASF SE

  公开号：US20160066573A1

  公开（公告）日：2016-03-10

  The invention relates to the use of a compound of formula (I) or a salt thereof for combating animal pests, where the symbols and indices are defined in the specification.
• SPRAY DRY FORMULATIONS
  申请人：ZISMAN Lawrence S.

  公开号：US20160235742A1

  公开（公告）日：2016-08-18

  Disclosed herein are compounds, compositions, and methods for preventing and treating proliferative diseases associated with aberrant receptor tyrosine kinase (RTK) activity. The therapeutic indications described herein more specifically relate to the non-selective inhibition of RTKs associated with vascular and pulmonary disorders.